These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 9728330

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. From Weed Killer to Wonder Drug.
    Lock EA.
    Adv Exp Med Biol; 2017; 959():175-185. PubMed ID: 28755195
    [Abstract] [Full Text] [Related]

  • 3. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).
    Holme E, Lindstedt S.
    J Inherit Metab Dis; 1998 Aug; 21(5):507-17. PubMed ID: 9728331
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione.
    Ellis MK, Whitfield AC, Gowans LA, Auton TR, Provan WM, Lock EA, Smith LL.
    Toxicol Appl Pharmacol; 1995 Jul; 133(1):12-9. PubMed ID: 7597701
    [Abstract] [Full Text] [Related]

  • 5. Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC).
    Pronicka E, Rowinska E, Bentkowski Z, Zawadzki J, Holme E, Lindstedt S.
    J Inherit Metab Dis; 1996 Jul; 19(2):234-8. PubMed ID: 8739974
    [No Abstract] [Full Text] [Related]

  • 6. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione.
    Mitchell GA.
    Hum Exp Toxicol; 1996 Feb; 15(2):179-81. PubMed ID: 8645506
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.
    Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B.
    Lancet; 1992 Oct 03; 340(8823):813-7. PubMed ID: 1383656
    [Abstract] [Full Text] [Related]

  • 8. The effect of a low-protein diet and dietary supplementation of threonine on tyrosine and 2-(2-nitro-4-trifluoromethylbenzoyl) cyclohexane-1,3-dione-induced corneal lesions, the extent of tyrosinemia, and the activity of enzymes involved in tyrosine catabolism in the rat.
    Lock EA, Gaskin P, Ellis MK, Robinson M, Provan WM, Smith LL.
    Toxicol Appl Pharmacol; 1998 May 03; 150(1):125-32. PubMed ID: 9630461
    [Abstract] [Full Text] [Related]

  • 9. Plasma antioxidant capacity in two cases of tyrosinaemia type 1: one case treated with NTBC.
    Bird S, Miller NJ, Collins JE, Rice-Evans CA.
    J Inherit Metab Dis; 1995 May 03; 18(2):123-6. PubMed ID: 7564225
    [No Abstract] [Full Text] [Related]

  • 10. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione.
    Molchanov S, Gryff-Keller A.
    Acta Biochim Pol; 2009 May 03; 56(3):447-54. PubMed ID: 19621095
    [Abstract] [Full Text] [Related]

  • 11. NTBC as palliative treatment in chronic tyrosinaemia type I.
    Ros J, Vilaseca MA, Lambruschini N, Mas A, Lindstedt S, Holme E.
    J Inherit Metab Dis; 1999 Jun 03; 22(5):665-6. PubMed ID: 10399099
    [No Abstract] [Full Text] [Related]

  • 12. Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) and its effect on enzymes involved in tyrosine catabolism in the mouse.
    Lock EA, Gaskin P, Ellis MK, McLean Provan W, Robinson M, Smith LL.
    Toxicology; 2000 Apr 03; 144(1-3):179-87. PubMed ID: 10781886
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers.
    Hall MG, Wilks MF, Provan WM, Eksborg S, Lumholtz B.
    Br J Clin Pharmacol; 2001 Aug 03; 52(2):169-77. PubMed ID: 11488774
    [Abstract] [Full Text] [Related]

  • 14. NTBC and alkaptonuria.
    Anikster Y, Nyhan WL, Gahl WA.
    Am J Hum Genet; 1998 Sep 03; 63(3):920-1. PubMed ID: 9718357
    [No Abstract] [Full Text] [Related]

  • 15. Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report.
    Grompe M, Overturf K, al-Dhalimy M, Finegold M.
    J Inherit Metab Dis; 1998 Aug 03; 21(5):518-31. PubMed ID: 9728332
    [Abstract] [Full Text] [Related]

  • 16. [Favorable outcome of treatment with NTBC of acute liver insufficiency disclosing hereditary tyrosinemia type I].
    Barkaoui E, Debray D, Habès D, Ogier H, Bernard O.
    Arch Pediatr; 1999 May 03; 6(5):540-4. PubMed ID: 10370811
    [Abstract] [Full Text] [Related]

  • 17. The role of nitisinone in tyrosine pathway disorders.
    Lock E, Ranganath LR, Timmis O.
    Curr Rheumatol Rep; 2014 Nov 03; 16(11):457. PubMed ID: 25266991
    [Abstract] [Full Text] [Related]

  • 18. Interaction of (4-hydroxyphenyl)pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione.
    Kavana M, Moran GR.
    Biochemistry; 2003 Sep 02; 42(34):10238-45. PubMed ID: 12939152
    [Abstract] [Full Text] [Related]

  • 19. Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1-3-dione (NTBC): effect on enzymes involved in tyrosine catabolism and relevance to ocular toxicity in the rat.
    Lock EA, Gaskin P, Ellis MK, Provan WM, Robinson M, Smith LL, Prisbylla MP, Mutter LC.
    Toxicol Appl Pharmacol; 1996 Dec 02; 141(2):439-47. PubMed ID: 8975769
    [Abstract] [Full Text] [Related]

  • 20. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.
    Santra S, Baumann U.
    Expert Opin Pharmacother; 2008 May 02; 9(7):1229-36. PubMed ID: 18422479
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.